These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 10092675

  • 1. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M.
    J Biol Chem; 1999 Apr 02; 274(14):9843-6. PubMed ID: 10092675
    [Abstract] [Full Text] [Related]

  • 2. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J, Uversky VN, Fink AL.
    Biochemistry; 2001 Sep 25; 40(38):11604-13. PubMed ID: 11560511
    [Abstract] [Full Text] [Related]

  • 3. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA, Harper JD, Lansbury PT.
    Biochemistry; 2000 Mar 14; 39(10):2552-63. PubMed ID: 10704204
    [Abstract] [Full Text] [Related]

  • 4. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.
    Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL.
    J Biol Chem; 1999 Jul 09; 274(28):19509-12. PubMed ID: 10391881
    [Abstract] [Full Text] [Related]

  • 5. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
    Li J, Uversky VN, Fink AL.
    Neurotoxicology; 2002 Oct 09; 23(4-5):553-67. PubMed ID: 12428728
    [Abstract] [Full Text] [Related]

  • 6. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA, Harper JD, Lansbury PT.
    Nat Med; 1998 Nov 09; 4(11):1318-20. PubMed ID: 9809558
    [Abstract] [Full Text] [Related]

  • 7. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
    Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT.
    Proc Natl Acad Sci U S A; 2000 Jan 18; 97(2):571-6. PubMed ID: 10639120
    [Abstract] [Full Text] [Related]

  • 8. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
    Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL.
    Proc Natl Acad Sci U S A; 2002 Jun 25; 99(13):8968-73. PubMed ID: 12084935
    [Abstract] [Full Text] [Related]

  • 9. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT.
    J Mol Biol; 2002 Oct 04; 322(5):1089-102. PubMed ID: 12367530
    [Abstract] [Full Text] [Related]

  • 10. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.
    Volles MJ, Lansbury PT.
    Biochemistry; 2002 Apr 09; 41(14):4595-602. PubMed ID: 11926821
    [Abstract] [Full Text] [Related]

  • 11. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
    El-Agnaf OM, Jakes R, Curran MD, Wallace A.
    FEBS Lett; 1998 Nov 27; 440(1-2):67-70. PubMed ID: 9862427
    [Abstract] [Full Text] [Related]

  • 12. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
    Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M.
    J Biol Chem; 2000 Nov 03; 275(44):34574-9. PubMed ID: 10942772
    [Abstract] [Full Text] [Related]

  • 13. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E, Fuller N, Rand RP, St George-Hyslop P, Fraser PE.
    J Mol Biol; 2002 Jan 25; 315(4):799-807. PubMed ID: 11812148
    [Abstract] [Full Text] [Related]

  • 14. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.
    Giasson BI, Uryu K, Trojanowski JQ, Lee VM.
    J Biol Chem; 1999 Mar 19; 274(12):7619-22. PubMed ID: 10075647
    [Abstract] [Full Text] [Related]

  • 15. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.
    Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA.
    Proc Natl Acad Sci U S A; 2000 Apr 25; 97(9):4897-902. PubMed ID: 10781096
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
    Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B.
    J Neurosci; 2000 Aug 15; 20(16):6048-54. PubMed ID: 10934254
    [Abstract] [Full Text] [Related]

  • 18. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM.
    Exp Neurol; 2004 Jun 15; 187(2):279-88. PubMed ID: 15144854
    [Abstract] [Full Text] [Related]

  • 19. The cell biology of alpha-synuclein: a sticky problem?
    Cole NB, Murphy DD.
    Neuromolecular Med; 2002 Jun 15; 1(2):95-109. PubMed ID: 12025860
    [Abstract] [Full Text] [Related]

  • 20. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.
    Bussell R, Eliezer D.
    Biochemistry; 2004 Apr 27; 43(16):4810-8. PubMed ID: 15096050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.